QuickCI read/Ophthalmology/Cell & Gene Tx Beacon Succeeded in XLRP Where Biogen and J&J Failed, on an Endpoint Neither of Them Used Athithi Verma· 22 September 2026· 2 min read· Synopulse Beacon Therapeutics said on 21 September 2026 that laru-zova met the FDA-endorsed primary endpoint of VISTA, a 12-month randomised trial in 85 males aged 12 … Read more
Every major regulator has now said yes to a strategy the FDA’s advisers doubted. The constraint is a blood test.
Without an upfront, a target or an isotope, BoomRay’s $900 million headline is a ceiling rather than a valuation.
The efficacy is the headline. The competitive case sits in the side effect line, and it points at AbbVie’s Vraylar.
Built in about three years for one mutation, it normalised a biomarker in one man. A larger cohort sits outside the paper.
CMS expects much of the coverage loss to come from process, not from failing the test. The insurer asked doctors to help.
Every instruction raises the number of diagnosed patients. None addresses what they can be prescribed, or who pays.
One exposure trial in lung cancer carried every Japanese indication. The contest is now minutes and millilitres.
The sellers receive shares, not cash, at closing, and $450m of the $700m earnout rests on a single year of sales.
Three routes to patients in four days. In a market that pays out of pocket, not one announcement carries a price.